
Slow Biosimilar Uptake in Latin America Signals Missed Opportunities for Patient Access, Cost Savings
Despite the recognized potential of biosimilars to expand patient access to critical biologic medicines and significantly reduce health care costs, their uptake in Latin American (LatAm) countries has remained notably slow.1 A recent manuscript, drawing on …